|
Accueil > Actualité
Roche: positive phase III data in breast cancer
(CercleFinance.com) - Roche announces positive phase III results for the combination of inavolisib in women with hormone receptor-advanced HER2-negative breast cancer with a PIK3CA mutation.
The INAVO120 study met its primary endpoint, demonstrating a statistically and clinically significant improvement in progression-free survival, compared to palbociclib and fulvestrant alone. Overall survival data was immature, although a clear positive trend was observed, the Swiss healthcare group said. The data will be shared with health authorities and presented at an upcoming medical meeting. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
23/05/2025 17:40
UbisoftBarclays détient moins de 5% du capital 23/05/2025 17:10 Legrandla société FIL détient plus de 5% du capital 23/05/2025 17:02 PublicisBlackRock détient plus de 5% des droits de votes 23/05/2025 16:50 AlstomBlackRock sous les 5% du capital & des votes 23/05/2025 16:00 J&Jprésentera 70 résumés lors du congrès de l'ASCO 23/05/2025 15:52 Generalien recul avec une dégradation d'analyste Tous les articles sociétés |
